Alphabet's life science arm also announces the company's founder Andy Conrad will step down as CEO. Current president Stephen Gillett will take on the role in January.
Sosei Heptares and Verily will collaborate to generate novel drug candidates against GPCR targets for immune-mediated diseasesResearch agreement combines Verily’s proprietary Immune Profiler platform with Sosei Heptares’ world-leading StaR® (stabilized receptor) platform and structure-based drug desi.
The companies share the goal of furthering knowledge around GPCR biology in immune cells in order to better understand a range of immune system disorders. - News - PharmaTimes
new research collaboration combining Verily’s Immune Profiler platform, a next gen immune mapping platform, with Sosei Heptares’ world-leading StaR (stabilized receptor) platform,